Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Apr / Cancer’s Common Core
Oncology Genetics and epigenetics Oncology Omics

Cancer’s Common Core

By Michael Schubert 04/27/2015 1 min read

Share

Genetic flaws shared by all metastases of a single prostate cancer may be the key to personalized treatment

In a landmark study by the International Cancer Genome Consortium (ICGC), scientists believe they have discovered the common genetic faults at the root of individual prostate cancers.

The ICGC Prostate Cancer UK group analyzed the genomes of tumor samples in 10 patients, allowing them to map the genetic changes that occurred as the tumors grew, metastasized and developed treatment resistance (1). They found massive genetic diversity between cells even when taken from different sites in the same prostate – but despite this diversity, the researchers were able to show that metastatic prostate cancer cells all share common mutations unique to the individual patient. In a Cancer Research UK press release (2), study author Ros Eeles said, “We found that all of the cells that had broken free shared a common ancestor cell in the prostate. The common faults we found in each man could potentially offer new targets for treatment.” Principal author Steven Bova agrees, saying, “The diversity we’ve found suggests multiple biopsies might be needed to identify the ‘trunk’ of the cancer’s tree of mutations – we need treatments that target these core weaknesses to destroy all cancer cells in a clean sweep.”

Eeles also reported that she and her group gained a much broader view of prostate cancer as a whole by studying both the original tumors and the cells that had metastasized. They discovered new information about the way prostate cancer spreads through the body (see infographic), using genetic evidence to show that the cells that initiate metastasis continue to travel through the circulatory system seeding additional tumors. However, Eeles adds the caveat that “once cancer cells have spread, they continue to evolve genetically, so choosing the most effective treatments will remain a key challenge.” For a disease that kills over 300,000 men worldwide each year (3), any step toward better treatment is welcome.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. G Gundem, et al., “The evolutionary history of lethal metastatic prostate cancer”, Nature, 520, 353–357 (2015). PMID: 25830880. Cancer Research UK, “Scientists drill down to genetic root of prostate tumour development” (2015). Available at: http://bit.ly/1G5i8PK. Accessed April 17, 2015. J Ferlay, et al. “GLOBOCAN 2012: Prostate cancer estimated incidence, mortality and prevalence worldwide in 2012” (2013). Available at: http://bit.ly/1aiP5Kv. Accessed April 17, 2015.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.